Monograph
S01BC10 - Nepafenac |
Not porphyrinogenic |
NP |
Rationale
Nepafenac is administered locally in the eye and hepatic exposure is insignificant.
Chemical description
Benzophenone
Therapeutic characteristics
Nepafenac is a non-steroid anti-inflammatory prodrug used in the treatment of postoperative pain and inflammation associated with cataract surgery (SPC). It is administered as eye drops.
Hepatic exposure
Following the 3 times daily dosing of nepafenac eye drops in both eyes, maximal plasma concentration of nepafenac and amfenak were in the order of 0,5 ng/ml (SPC) which is well below 1,0 µM concentration and hepatic exposure is therefore regarded as insignificant.
Metabolism and pharmacokinetics
Nepafenac is converted by ocular tissue hydrolases to the active drug amfenac. Amfenac is further hydroxylated, bound to glucoronic acid and excreted as glucuronide conjugates (SPC).
In vitro studies show that neither nepafenac nor amfenac show inhibitory effects on the major CYP450 metabolizing enzymes (CYP3A4, CYP2C9) (SPC).
Similar drugs
References
| # | Citation details | PMID |
|---|---|---|
| * | Summary of Product Characteristics | |
| 1. | The electronic Medicines Compendium (eMC). Nevanac. Summary of Product Characteristics (SPC).
|
|
Tradenames
This list comprises raw data collected from different countries.
In some cases, a more comprehensive list of available drug packages is included.
Consequently, very similar terms may therefore appear multiple times.
Bold names are the searchable terms, while the gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
Nevanac 
Nevanac 
Nevanac 
Nevanac 
Nevanac 
Nevanac 
Nevanac 
Nevanac 
Nevanac 
Nevanac 
Nevanac 
Nevanac 
Nevanac
© NAPOS 2025